Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors

Weiguang Wang, S. Marsh, J. Cassidy, H. L. McLeod

    Research output: Contribution to journalArticle

    60 Citations (Scopus)

    Abstract

    Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines, YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (> 10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.

    Original languageEnglish
    Pages (from-to)5505-5510
    Number of pages5
    JournalCancer Research
    Volume61
    Issue number14
    Publication statusPublished - 2001

    Keywords

    • COMPARATIVE GENOMIC HYBRIDIZATION
    • CELL-LINES
    • COLORECTAL-CANCER
    • SOLID TUMORS
    • PHASE-I
    • CARCINOMA
    • TOMUDEX

    Cite this

    Wang, W., Marsh, S., Cassidy, J., & McLeod, H. L. (2001). Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Research, 61(14), 5505-5510.

    Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. / Wang, Weiguang; Marsh, S.; Cassidy, J.; McLeod, H. L.

    In: Cancer Research, Vol. 61, No. 14, 2001, p. 5505-5510.

    Research output: Contribution to journalArticle

    Wang, W, Marsh, S, Cassidy, J & McLeod, HL 2001, 'Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors', Cancer Research, vol. 61, no. 14, pp. 5505-5510.
    Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Research. 2001;61(14):5505-5510.
    Wang, Weiguang ; Marsh, S. ; Cassidy, J. ; McLeod, H. L. / Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. In: Cancer Research. 2001 ; Vol. 61, No. 14. pp. 5505-5510.
    @article{e663736c55ef469ca980923d6a13c754,
    title = "Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors",
    abstract = "Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines, YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (> 10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.",
    keywords = "COMPARATIVE GENOMIC HYBRIDIZATION, CELL-LINES, COLORECTAL-CANCER, SOLID TUMORS, PHASE-I, CARCINOMA, TOMUDEX",
    author = "Weiguang Wang and S. Marsh and J. Cassidy and McLeod, {H. L.}",
    year = "2001",
    language = "English",
    volume = "61",
    pages = "5505--5510",
    journal = "Cancer Research",
    issn = "0008-5472",
    publisher = "AMER ASSOC CANCER RESEARCH",
    number = "14",

    }

    TY - JOUR

    T1 - Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors

    AU - Wang, Weiguang

    AU - Marsh, S.

    AU - Cassidy, J.

    AU - McLeod, H. L.

    PY - 2001

    Y1 - 2001

    N2 - Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines, YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (> 10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.

    AB - Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines, YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (> 10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.

    KW - COMPARATIVE GENOMIC HYBRIDIZATION

    KW - CELL-LINES

    KW - COLORECTAL-CANCER

    KW - SOLID TUMORS

    KW - PHASE-I

    KW - CARCINOMA

    KW - TOMUDEX

    M3 - Article

    VL - 61

    SP - 5505

    EP - 5510

    JO - Cancer Research

    JF - Cancer Research

    SN - 0008-5472

    IS - 14

    ER -